These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 8910761

  • 1. Mouse myeloma cell line secreting bifunctional fusion protein RM4/IFN-gamma [corrected] elicits antitumor CD8 MHC class I-restricted T cells that are cytolytic in vitro and tumoricidal in vivo.
    Qi Y, Chen Y, Xiang J.
    J Interferon Cytokine Res; 1996 Oct; 16(10):771-6. PubMed ID: 8910761
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of established tumor growth in syngeneic mice by local inoculation of engineered mouse myeloma cells secreting a recombinant fusion protein RM4/TNF.
    Xiang J, Qi Y, Chen Y.
    Cancer Gene Ther; 1997 Oct; 4(6):353-8. PubMed ID: 9408605
    [Abstract] [Full Text] [Related]

  • 3. Antitumor vaccination with gene-transduced tumor cells expressing a fusion protein RM4/IFN-tau.
    Xiang J.
    Cancer Biother Radiopharm; 1997 Apr; 12(2):123-30. PubMed ID: 10851456
    [Abstract] [Full Text] [Related]

  • 4. Characterization of anti-tumor immunity derived from the inoculation of myeloma cells secreting the fusion protein RM4/IFN-tau.
    Qi Y, Moyana T, Chen Y, Xiang J.
    Hum Antibodies Hybridomas; 1996 Apr; 7(1):21-6. PubMed ID: 8886833
    [Abstract] [Full Text] [Related]

  • 5. Cytotoxic CD4+ T cells associated with the expression of major histocompatibility complex class II antigen of mouse myeloma cells secreting interferon-gamma are cytolytic in vitro and tumoricidal in vivo.
    Xiang J, Moyana T.
    Cancer Gene Ther; 1998 Apr; 5(5):313-20. PubMed ID: 9824051
    [Abstract] [Full Text] [Related]

  • 6. Intratumoral vaccination of adenoviruses expressing fusion protein RM4/tumor necrosis factor (TNF)-alpha induces significant tumor regression.
    Wright P, Zheng C, Moyana T, Xiang J.
    Cancer Gene Ther; 1998 Apr; 5(6):371-9. PubMed ID: 9917092
    [Abstract] [Full Text] [Related]

  • 7. Regression of engineered tumor cells secreting cytokines is related to a shift in host cytokine profile from type 2 to type 1.
    Xiang J, Moyana T.
    J Interferon Cytokine Res; 2000 Apr; 20(4):349-54. PubMed ID: 10805368
    [Abstract] [Full Text] [Related]

  • 8. Targeting gamma interferon to tumor cells by a genetically engineered fusion protein secreted from myeloma cells.
    Xiang J, Qi Y, Cook D, Moyana T.
    Hum Antibodies Hybridomas; 1996 Apr; 7(1):2-10. PubMed ID: 8886831
    [Abstract] [Full Text] [Related]

  • 9. Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.
    Xie Y, Bai O, Zhang H, Li W, Xiang J.
    Cancer Biother Radiopharm; 2010 Feb; 25(1):21-8. PubMed ID: 20187793
    [Abstract] [Full Text] [Related]

  • 10. Significant tumor regression induced by microencapsulation of recombinant tumor cells secreting fusion protein.
    Shi M, Hao S, Quereshi M, Guo X, Zheng C, Xiang J.
    Cancer Biother Radiopharm; 2005 Jun; 20(3):260-6. PubMed ID: 15989471
    [Abstract] [Full Text] [Related]

  • 11. Rat mammary adenocarcinoma 13762 expressing IFN-gamma elicits antitumor CD4+ MHC class II-restricted T cells that are cytolytic in vitro and tumoricidal in vivo.
    Frey AB.
    J Immunol; 1995 May 01; 154(9):4613-22. PubMed ID: 7722313
    [Abstract] [Full Text] [Related]

  • 12. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer.
    Xiang J, Chen Y, Moyana T.
    Cancer Gene Ther; 2000 Jul 01; 7(7):1023-33. PubMed ID: 10917205
    [Abstract] [Full Text] [Related]

  • 13. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D, Dubey S, Van Veldhuizen P, Holzbeierlein JM, Tawfik O, Thrasher JB.
    Immunotherapy; 2011 Jun 01; 3(6):735-46. PubMed ID: 21668311
    [Abstract] [Full Text] [Related]

  • 14. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity.
    Bannerji R, Arroyo CD, Cordon-Cardo C, Gilboa E.
    J Immunol; 1994 Mar 01; 152(5):2324-32. PubMed ID: 7907636
    [Abstract] [Full Text] [Related]

  • 15. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
    Merritt RE, Yamada RE, Crystal RG, Korst RJ.
    J Thorac Cardiovasc Surg; 2004 Feb 01; 127(2):355-64. PubMed ID: 14762342
    [Abstract] [Full Text] [Related]

  • 16. Sufficiency of the CD8+ T cell lineage to mount an effective tumoricidal response to syngeneic tumor-bearing novel class I MHC antigens.
    Fan ST, Edgington TS.
    J Immunol; 1989 Dec 15; 143(12):4287-91. PubMed ID: 2531780
    [Abstract] [Full Text] [Related]

  • 17. [Immunization with dendritic cells infected with mTERT adenovirus vector effectively elicits immunity against mouse H22 hepatoma in vivo].
    Jiang N, Wang GS, Li H, Zhang J, Zhang JF, Yi SH, Yi HM, Yang Y, Cai CJ, Lu MQ, Chen GH.
    Zhonghua Zhong Liu Za Zhi; 2009 Jun 15; 31(6):405-9. PubMed ID: 19950546
    [Abstract] [Full Text] [Related]

  • 18. The NS2 protein of human respiratory syncytial virus suppresses the cytotoxic T-cell response as a consequence of suppressing the type I interferon response.
    Kotelkin A, Belyakov IM, Yang L, Berzofsky JA, Collins PL, Bukreyev A.
    J Virol; 2006 Jun 15; 80(12):5958-67. PubMed ID: 16731934
    [Abstract] [Full Text] [Related]

  • 19. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.
    Int J Oncol; 2006 Apr 15; 28(4):947-53. PubMed ID: 16525645
    [Abstract] [Full Text] [Related]

  • 20. NK 1+ CD4- CD8- alphabeta T cells in the peritoneal cavity: specific T cell receptor-mediated cytotoxicity and selective IFN-gamma production against B cell leukemia and myeloma cells.
    Sugie T, Kubota H, Sato M, Nakamura E, Imamura M, Minato N.
    J Immunol; 1996 Nov 01; 157(9):3925-35. PubMed ID: 8892624
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.